Skip to content
Menu

Guggenheim Maintains Buy on Jade Biosciences, Lowers Price Target to $41

Benzinga Newsdesk 5 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Guggenheim analyst Vamil Divan maintains Jade Biosciences (NASDAQ:JBIO) with a Buy and lowers the price target from $47 to $41.

Guggenheim analyst Vamil Divan maintains Jade Biosciences (NASDAQ:JBIO) with a Buy and lowers the price target from $47 to $41.

Read at benzinga.com